Mary Wells, MD
Hematology & Oncology · Omaha, NENPI 1538508296
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by AstraZeneca at 54.3% of the total. Reporting peaked in 2023 at $2,206 and has fallen 61.3% since, to $854 in 2025. That places this record below the midpoint for hematology & oncology clinicians in NE, where the typical reported total is $3,016.
Across 35 payments — averaging $102.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Abiomed$719
- Incyte Corporation$216
- Intuitive Surgical$169
- Novocure Inc.$125
- E.r. Squibb & Sons, L.L.C.$79
- plus $336 from 13 others
Across 70 payments — averaging $22,249 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$961K
- Genentech, Inc.$330K
- Mirati Therapeutics, Inc.$246K
- Tolmar, Inc.$13K
- Amgen$7K
What the payments were for
- Consulting fees$1,94354%
- Travel & lodging$3379%
- Food & beverage$1,30336%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $1,951 |
| Abiomed | 7 | $719 |
| Incyte Corporation | 1 | $216 |
| Intuitive Surgical | 2 | $169 |
| Novocure Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 5 | $79 |
| Daiichi Sankyo Inc. | 3 | $50 |
| Siemens Medical Solutions USA, Inc. | 1 | $43 |
| Novartis | 2 | $37 |
| AbbVie | 1 | $31 |
| Sanofi | 2 | $28 |
| Genentech USA, Inc. | 1 | $28 |
| Boston Scientific | 1 | $23 |
| Pfizer | 1 | $21 |
| Octapharma USA, Inc. | 1 | $18 |
| Merck | 1 | $17 |
| G1 Therapeutics, Inc. | 1 | $15 |
| Seagen Inc. | 1 | $14 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,595 in reported general payments places this provider in the 50th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 24 | $388,139 |
| Lenalidomide | 22 | $319,397 |
| TagrissoOsimertinib Mesylate | 12 | $197,123 |
| BrukinsaZanubrutinib | 12 | $188,029 |
| VerzenioAbemaciclib | 11 | $166,101 |
| Abiraterone Acetate | 13 | $36,885 |
| EliquisApixaban | 20 | $24,479 |
| XareltoRivaroxaban | 31 | $22,737 |
| CreonLipase/Protease/Amylase | 12 | $10,132 |
| Exemestane | 43 | $9,525 |
| Letrozole | 435 | $7,591 |
| Enoxaparin Sodium | 17 | $4,690 |
| Voriconazole | 11 | $3,384 |
| Tamoxifen Citrate | 86 | $1,666 |
| Anastrozole | 72 | $1,600 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $21 | $412,61844 claims |
| AstraZenecaTagrisso | $1,951 | $197,12312 claims |
| AbbVieCreon | $31 | $10,13212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 73 hematology & oncology providers in Nebraska.
Other hematology & oncology in Omaha
- Mojtaba AkhtariOmaha$1.8M
- Luke NordquistOmaha$202K
- Apar Kishor GantiOmaha$138K
- Julie VoseOmaha$123K
- Peter SilbersteinOmaha$99K
- Krishna GundaboluOmaha$76K
- Vijaya BhattOmaha$58K
- Samer RennoOmaha$41K
- Timothy DoriusOmaha$24K
- Stefano TarantoloOmaha$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.